Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer

Cancer Immunology, Immunotherapy

Volumn 66, Issue 10, 2017, Pages 1345-1357

  Sonpavde, Guru ^a   McMannis, John D ^b,c   Bai, Yu ^d   Seethammagari, Mamatha R ^e   Bull, Joan M C ^d   Hawkins, Victoria ^d   Dancsak, Theresa K ^d   Lapteva, Natasha ^e   Levitt, Jonathan M ^e   Moseley, Annemarie ^f   Spencer, David M ^f   Slawin, Kevin M ^f  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c Mesoblast Limited   (Australia)

^d UNIVERSITY OF TEXAS   (United States)

^e BAYLOR COLLEGE OF MEDICINE   (United States)

^f Bellicum Pharmaceuticals   (United States)

Author keywords

Castration resistant prostate cancer; Dendritic cell vaccine; Immune response; Metastatic; PSMA; Rimiducid

Indexed keywords

ADENOVIRUS VECTOR; BPX 101; CABAZITAXEL; CANCER VACCINE; CD40 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RANTES; RIMIDUCID; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ANEMIA; ANXIETY DISORDER; APPLICATION SITE EXCORIATION; APPLICATION SITE PAIN; ARTHRALGIA; ARTICLE; BACKACHE; BLADDER SPASM; CANCER GROWTH; CANCER IMMUNOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; CELL MATURATION; CIRCULATING TUMOR CELL; COHORT ANALYSIS; CONTUSION; CYSTALGIA; CYTOKINE RELEASE SYNDROME; DEHYDRATION; DENDRITIC CELL; DEPRESSION; DIARRHEA; DIZZINESS; DRUG ACTIVITY; DRUG SAFETY; FAINTNESS; FATIGUE; FEVER; FLANK PAIN; FLU LIKE SYNDROME; FOOT FRACTURE; HEADACHE; HEMATURIA; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDRONEPHROSIS; HYPOCALCEMIA; IMMUNE RESPONSE; IN VIVO STUDY; INGUINAL PAIN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE REACTION; INSOMNIA; INTESTINE OBSTRUCTION; KARNOFSKY PERFORMANCE STATUS; LEUKAPHERESIS; LUNG EMBOLISM; MALE; METASTATIC CASTRATION RESISTANT PROSTATE CANCER; MYALGIA; NAUSEA; NEUROLOGIC DISEASE; OROPHARYNX PAIN; ORTHOSTATIC HYPERTENSION; ORTHOSTATIC HYPOTENSION; PELVIC PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOKINETIC PARAMETERS; PHLEBITIS; PRIORITY JOURNAL; PROPHYLAXIS; PROTEINURIA; RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; THRUSH; TUMOR REGRESSION; UPPER RESPIRATORY TRACT INFECTION; UPREGULATION; VACCINATION; VERTIGO; VOMITING; CLINICAL TRIAL; IMMUNOLOGY; METABOLISM; PHASE 1 CLINICAL TRIAL; PROSTATE TUMOR;

AGED; CANCER VACCINES; CD40 ANTIGENS; COHORT STUDIES; DENDRITIC CELLS; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 85020736353     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-017-2027-6     Document Type: Article

References (39)

1. Tannock IF, de Wit R, Berry WR et al (2004) Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351:1502–1512. doi:10.1056/NEJMoa040720
2. Petrylak DP, Tangen CM, Hussain MH et al (2004) Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351:1513–1520. doi:10.1056/NEJMoa041318
3. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
4. de Bono JS, Oudard S, Ozguroglu M et al (2010) Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376:1147–1154. doi:10.1016/S0140-6736(10)61389-X
5. de Bono JS, Logothetis CJ, Molina A et al (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995–2005. doi:10.1056/NEJMoa1014618
6. Scher HI, Fizazi K, Saad F et al (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187–1197. doi:10.1056/NEJMoa1207506
7. Parker C, Nilsson S, Heinrich D et al (2013) Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369:213–223. doi:10.1056/NEJMoa1213755
8. Ryan CJ, Smith MR, de Bono JS et al (2013) Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 368:138–148. doi:10.1056/NEJMoa1209096
9. Beer TM, Armstrong AJ, Rathkopf DE et al (2014) Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 371:424–433. doi:10.1056/NEJMoa1405095
10. Kantoff PW, Higano CS, Shore ND et al (2010) Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363:411–422. doi:10.1056/NEJMoa1001294
11. Higano CS, Schellhammer PF, Small EJ, Burch PA, Nemunaitis J, Yuh L, Provost N, Frohlich MW (2009) Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 115:3670–3679. doi:10.1002/cncr.24429
12. Kikuchi T, Worgall S, Singh R, Moore MA, Crystal RG (2000) Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat Med 6:1154–1159. doi:10.1038/80498
13. Hanks BA, Jiang J, Singh RA, Song W, Barry M, Huls MH, Slawin KM, Spencer DM (2005) Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. Nat Med 11:130–137. doi:10.1038/nm1183
14. Lapteva N, Seethammagari MR, Hanks BA, Jiang J, Levitt JM, Slawin KM, Spencer DM (2007) Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. Can Res 67:10528–10537. doi:10.1158/0008-5472.CAN-07-0833
15. Iuliucci JD, Oliver SD, Morley S, Ward C, Ward J, Dalgarno D, Clackson T, Berger HJ (2001) Intravenous safety and pharmacokinetics of a novel dimerizer drug, AP1903, in healthy volunteers. J Clin Pharmacol 41:870–879
16. Di Stasi A, Tey SK, Dotti G et al (2011) Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med 365:1673–1683. doi:10.1056/NEJMoa1106152
17. Clackson T, Yang W, Rozamus LW et al (1998) Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity. Proc Natl Acad Sci USA 95:10437–10442
18. Wright GL Jr, Grob BM, Haley C et al (1996) Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 48:326–334
19. Liu H, Moy P, Kim S, Xia Y, Rajasekaran A, Navarro V, Knudsen B, Bander NH (1997) Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Can Res 57:3629–3634
20. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228–247. doi:10.1016/j.ejca.2008.10.026
21. Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148–1159. doi:10.1200/JCO.2007.12.4487
22. Xing D, Decker WK, Li S et al (2006) AML-loaded DC generate Th1-type cellular immune responses in vitro. Cytotherapy 8:95–104. doi:10.1080/14653240600620093
23. Decker WK, Xing D, Li S et al (2006) Double loading of dendritic cell MHC class I and MHC class II with an AML antigen repertoire enhances correlates of T-cell immunity in vitro via amplification of T-cell help. Vaccine 24:3203–3216. doi:10.1016/j.vaccine.2006.01.029
24. Scher HI, Heller G, Molina A et al (2015) Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer. J Clin Oncol 33:1348–1355. doi:10.1200/JCO.2014.55.3487
25. Rini BI, Weinberg V, Bok R, Small EJ (2003) Prostate-specific antigen kinetics as a measure of the biologic effect of granulocyte-macrophage colony-stimulating factor in patients with serologic progression of prostate cancer. J Clin Oncol 21:99–105
26. Small EJ, Reese DM, Um B, Whisenant S, Dixon SC, Figg WD (1999) Therapy of advanced prostate cancer with granulocyte macrophage colony-stimulating factor. Clin Cancer Res 5:1738–1744
27. Small E, Demkow T, Gerritsen WR et al (2009) A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel versus docetaxel plus prednisone in symptomatic, castration-resistant prostate cancer (CRPC). In: Proceedings genitourinary cancer symposium. Orlando, 26–28 February 2009 (abstract 7)
28. Higano CS, Saad F, Curti BD et al (2009) A phase III trial of GVAX immunotherapy for prostate cancer versus docetaxel plus prednisone in asymptomatic, castration-resistant prostate cancer (CRPC). In: Proceedings genitourinary cancers symposium. Orlando, 26–28 February 2009 (abstract LBA150)
29. Sheikh NA, Petrylak D, Kantoff PW et al (2013) Sipuleucel-T immune parameters correlate with survival: an analysis of the randomized phase 3 clinical trials in men with castration-resistant prostate cancer. Cancer Immunol Immunother 62:137–147. doi:10.1007/s00262-012-1317-2
30. Fong L, Carroll P, Weinberg V et al (2014) Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. J Natl Cancer Inst. doi:10.1093/jnci/dju268
31. Kwon ED, Drake CG, Scher HI et al (2014) Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 15:700–712. doi:10.1016/S1470-2045(14)70189-5
32. Topalian SL, Hodi FS, Brahmer JR et al (2012) Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 366:2443–2454. doi:10.1056/NEJMoa1200690
33. Kantoff PW, Schuetz TJ, Blumenstein BA et al (2010) Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 28:1099–1105. doi:10.1200/JCO.2009.25.0597
34. Podrazil M, Horvath R, Becht E et al (2015) Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. Oncotarget 6:18192–18205. doi:10.18632/oncotarget.4145
35. Yoshimura K, Minami T, Nozawa M, Kimura T, Egawa S, Fujimoto H, Yamada A, Itoh K, Uemura H (2016) A phase 2 randomized controlled trial of personalized peptide vaccine immunotherapy with low-dose dexamethasone versus dexamethasone alone in chemotherapy-naive castration-resistant prostate cancer. Eur Urol 70:35–41. doi:10.1016/j.eururo.2015.12.050
36. McNeel DG, Dunphy EJ, Davies JG et al (2009) Safety and immunological efficacy of a DNA vaccine encoding prostatic acid phosphatase in patients with stage D0 prostate cancer. J Clin Oncol 27:4047–4054. doi:10.1200/JCO.2008.19.9968
37. Miles BJ, Shalev M, Aguilar-Cordova E et al (2001) Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum Gene Ther 12:1955–1967. doi:10.1089/104303401753204535
38. Herman JR, Adler HL, Aguilar-Cordova E, Rojas-Martinez A, Woo S, Timme TL, Wheeler TM, Thompson TC, Scardino PT (1999) In situ gene therapy for adenocarcinoma of the prostate: a phase I clinical trial. Hum Gene Ther 10:1239–1249. doi:10.1089/10430349950018229
39. Narayanan P, Lapteva N, Seethammagari M, Levitt JM, Slawin KM, Spencer DM (2011) A composite MyD88/CD40 switch synergistically activates mouse and human dendritic cells for enhanced antitumor efficacy. J Clin Investig 121:1524–1534. doi:10.1172/JCI44327